Chronic kidney disease (CKD) is classified into five stages based on how well the kidneys filter blood, measured by an estimate called the glomerular filtration rate (GFR). Stage 1 represents mild kidney damage with normal or high filtration, while stage 5 represents kidney failure. The staging system sounds straightforward, but what happens inside the body at each stage, and how doctors actually measure and interpret the numbers, is more layered than the five-tier label suggests.
How the Five Stages Are Defined
The global standard for staging comes from KDIGO (Kidney Disease: Improving Global Outcomes), an international guideline body. Staging is based on the estimated GFR (eGFR), which approximates how many milliliters of blood your kidneys filter per minute, adjusted for body size. The thresholds are:
- Stage 1: eGFR 90 or above, with evidence of kidney damage such as protein in the urine or structural abnormalities on imaging.
- Stage 2: eGFR 60 to 89, again with evidence of damage. Without that evidence, a mildly reduced eGFR alone does not qualify as CKD.
- Stage 3a: eGFR 45 to 59.
- Stage 3b: eGFR 30 to 44.
- Stage 4: eGFR 15 to 29.
- Stage 5: eGFR below 15, or on dialysis.
The split of stage 3 into 3a and 3b was introduced because the risk of complications and progression to kidney failure differs sharply between an eGFR of 55 and an eGFR of 32. KDIGO also layers in albuminuria staging at every GFR category, because the amount of protein leaking into the urine is an independent predictor of how quickly things get worse.1Kidney International. The definition, classification, and prognosis of chronic kidney disease: a KDIGO Controversies Conference report A person at stage 3a with very little protein in the urine has a fundamentally different outlook than a person at stage 3a with heavy proteinuria, even though their eGFR numbers might be identical.
What Stages 1 and 2 Feel Like (Usually Nothing)
Most people with early CKD have no symptoms at all. The kidneys have enormous reserve capacity, and losing some filtration rarely produces noticeable effects when eGFR stays above 60. That is exactly what makes early detection so dependent on lab work rather than symptoms. A routine blood test or a urine screen showing persistent protein is often the first clue.
Underneath the silence, though, damage is accumulating. A key early process involves surviving nephrons (the kidney’s individual filtering units) compensating for lost ones by working harder. Each remaining nephron ramps up its own filtration rate, which temporarily maintains overall kidney function. But the increased pressure and size changes in those overworked nephrons drive further damage, including protein leaking into the urine and stress on the surrounding tissue.2PubMed Central. Glomerular hyperfiltration as a therapeutic target for CKD This compensatory overwork can mask the true extent of nephron loss, which is why eGFR may look normal or only slightly reduced even though a meaningful chunk of kidney tissue is already gone.3PubMed Central. How Do Kidneys Adapt to a Deficit or Loss in Nephron Number?
The two biggest drivers of CKD are diabetes and high blood pressure, and they often travel together. A large prospective cohort study found that having both conditions produced a synergistic increase in the risk of developing new CKD, greater than what either condition alone would predict.4PubMed Central. The effects of hypertension and diabetes on new-onset chronic kidney disease: A prospective cohort study That synergy is one reason blood pressure and blood sugar control get so much attention in early-stage kidney care.
Stage 3 and the Complications That Start Building
Stage 3 is where the clinical picture begins to change. With eGFR between 30 and 59, the kidneys are losing their ability to regulate several behind-the-scenes processes that most people never think about until they go wrong: making red blood cells, managing phosphorus and calcium, keeping potassium in check, and maintaining the acid-base balance of the blood.
Anemia is one of the earliest complications. The kidneys produce erythropoietin (EPO), the hormone that tells bone marrow to make red blood cells. As kidney function declines, EPO production falls behind what the body needs. In one study of anemic patients, a relative deficiency of EPO was present in about two thirds of those with stage 3 CKD, rising to 93 percent in stage 4 and essentially 100 percent in stage 5.5Nephrology Dialysis Transplantation. Serum erythropoietin concentrations and responses to anaemia in patients with or without chronic kidney disease Anemia causes fatigue, shortness of breath, and poor exercise tolerance, symptoms that patients sometimes chalk up to aging or stress rather than a kidney problem.
Bone and mineral metabolism also starts going off track around stage 3. As fewer nephrons are available to excrete phosphorus, the body compensates by ramping up two hormones: FGF23, produced by bone cells, and parathyroid hormone (PTH). These hormones push remaining nephrons to excrete more phosphorus per unit, but the tradeoff is that active vitamin D production drops, which in turn reduces calcium absorption from food. The result is a slowly escalating cycle of rising PTH, falling calcium, and eventually, in advanced stages, overt high phosphorus levels.6Endocrinology and Metabolism. Roles of Parathyroid Hormone and Fibroblast Growth Factor 23 in Advanced Chronic Kidney Disease Over time, this process leads to weaker bones with increased fracture risk and calcification of blood vessels and heart valves.7PubMed. Chronic Kidney Disease-Mineral and Bone Disorders: Pathogenesis and Management
Stages 4 and 5: When the Body Can No Longer Compensate
By stage 4 (eGFR 15 to 29), the kidneys can no longer keep up with the body’s waste products. Toxins that are normally filtered out of the blood, compounds like indoxyl sulfate and p-cresyl sulfate, accumulate and start damaging other organs. This buildup of waste products, called uremia, contributes to the progression of CKD itself and raises cardiovascular risk substantially.8PubMed Central. Uremic Toxins in the Progression of Chronic Kidney Disease and Cardiovascular Disease: Mechanisms and Therapeutic Targets
Two other problems intensify in stages 4 and 5. One is high potassium (hyperkalemia). Healthy kidneys excrete most of the body’s potassium, and when that excretion drops, potassium can rise to levels that threaten heart rhythm.9PubMed Central. Hyperkalemia in Chronic Kidney Disease: Links, Risks and Management The other is metabolic acidosis, a condition in which the blood becomes too acidic because the kidneys can no longer excrete enough acid. Roughly 30 percent of patients with advanced CKD develop metabolic acidosis, which accelerates muscle wasting, bone loss, and further kidney decline.10PubMed. Importance of Metabolic Acidosis as a Health Risk in Chronic Kidney Disease
Stage 5, often called kidney failure, is the point at which most people need some form of renal replacement therapy (dialysis or transplant) to stay alive. Symptoms by this point can include severe fatigue, nausea, confusion, swelling, difficulty breathing, and itching. Many patients describe feeling profoundly unwell in ways that are hard to localize to one symptom.
The Heart-Kidney Connection
Cardiovascular disease is the leading cause of death in people with CKD, and the relationship runs in both directions. The American Heart Association classifies these interactions under the term “cardiorenal syndrome,” recognizing that dysfunction in one organ directly induces dysfunction in the other through hemodynamic shifts, hormonal changes, and inflammation.11PubMed. Cardiorenal Syndrome: Classification, Pathophysiology, Diagnosis, and Treatment Strategies: A Scientific Statement From the American Heart Association
The cardiovascular damage is not something that waits until late-stage kidney disease. Risk factors including high blood pressure, volume overload, anemia, and uremic toxin buildup begin their effects once eGFR falls below 60, triggering inflammation, stiffening of blood vessel walls, and changes in heart structure such as thickening of the left ventricle.12PubMed Central. Cardiovascular Alterations and Structural Changes in the Setting of Chronic Kidney Disease: a Review of Cardiorenal Syndrome Type 4 This is why many people with moderate CKD die of a heart attack or heart failure long before they ever reach stage 5. For the individual patient, managing cardiovascular risk is at least as important as slowing the kidney decline itself.
How eGFR Is Measured and Where It Can Go Wrong
Most eGFR values come from a blood test measuring creatinine, a waste product of muscle metabolism. A formula converts the creatinine level, along with age and sex, into an estimated filtration rate. The catch is that creatinine levels are influenced by muscle mass, diet, and other factors that have nothing to do with how well the kidneys are filtering. A muscular person and a frail elderly person with the same true kidney function will have different creatinine levels.
An alternative marker called cystatin C is less affected by muscle mass. Studies comparing the two approaches found that cystatin C-based eGFR shifted about a quarter of patients to a later (more severe) CKD stage compared to the creatinine-based estimate, while only about 7 percent moved to an earlier stage.13Kidney Medicine. Estimated GFR With Cystatin C and Creatinine in Clinical Practice: A Retrospective Cohort Study In large general-population cohorts, more people qualified as having reduced kidney function when cystatin C was used instead of creatinine, and reclassification by cystatin C better predicted who would go on to develop serious outcomes like kidney failure or death.14PubMed Central. Cystatin C versus Creatinine in Determining Risk Based on Kidney Function
Another significant change in recent years has been the removal of a race-based adjustment factor from the most widely used eGFR equations. Older formulas produced higher eGFR values for Black patients, which could delay recognition of kidney disease and referrals for transplant evaluation. The 2021 CKD-EPI equations dropped race from the calculation entirely. Compared with the older formulas, the new creatinine equations increased estimates of CKD prevalence among Black patients while producing similar or lower prevalence among non-Black populations.15PubMed Central. New Creatinine- and Cystatin C-Based Equations to Estimate GFR without Race A Canadian study found that roughly 17 percent of patients were reclassified under the new equation, and those reclassified to a higher eGFR category had a 22 percent lower risk of progressing to kidney failure, suggesting the old formula had been overstaging some individuals.16PubMed Central. Implications of Implementing the 2021 CKD-EPI Equation Without Race on Managing Patients With Kidney Disease in British Columbia, Canada
Staging Challenges in Children
The adult staging thresholds apply to children as well, but estimating GFR accurately in a growing child is harder. Creatinine levels in children depend heavily on height, age, and muscle development, all of which change rapidly. Pediatric-specific equations exist, but even the best of them have substantial imprecision. One study of pediatric transplant recipients found that all eight tested eGFR equations overestimated kidney function in children whose true GFR was low and underestimated it in children with normal function, correctly classifying patients into the right CKD stage only about a third of the time.17PubMed Central. The impact of estimated glomerular filtration rate equations on chronic kidney disease staging in pediatric renal or heart transplant recipients For children with CKD, clinicians often rely on specialized formulas and, when precision matters most, direct GFR measurements rather than estimates.18PubMed. Estimating pediatric glomerular filtration rates in the era of chronic kidney disease staging
Slowing the Decline With Medications and Diet
Two drug classes have been the backbone of kidney protection for decades: ACE inhibitors and angiotensin receptor blockers (ARBs), collectively called RAS inhibitors. They work by reducing the pressure inside the glomeruli, the tiny filtering clusters in the kidneys. A newer class of drugs called SGLT2 inhibitors, originally developed for diabetes, has proven to be powerfully kidney-protective through a related but distinct mechanism. SGLT2 inhibitors cause more sodium to reach a sensor structure in the nephron, which triggers constriction of the vessel feeding the glomerulus and thereby lowers the pressure inside it.19PubMed Central. Renal Protection with SGLT2 Inhibitors: Effects in Acute and Chronic Kidney Disease They also appear to reduce inflammation and improve oxygen delivery to kidney tissue.20PubMed. Renoprotective mechanisms of sodium-glucose co-transporter 2 (SGLT2) inhibitors against the progression of diabetic kidney disease
When SGLT2 inhibitors are combined with RAS inhibitors, the effect appears to be greater than either alone. A nationwide cohort study of patients with both diabetes and hypertension found that the combination enhanced kidney protection across the CKD spectrum, consistent with the two drugs lowering glomerular pressure through complementary pathways.21PubMed Central. Effects of RAS and SGLT2 inhibitors alone or in combination on end-stage kidney disease and/or all-cause death in patients with both diabetes and hypertension: a nationwide cohort study One initially alarming feature of SGLT2 inhibitors is a small dip in eGFR when they are first started, typically around 3 to 5 points. That dip reflects the intended reduction in glomerular pressure, is reversible on stopping the drug, and actually predicts better long-term kidney outcomes.
Diet also plays a role. A systematic review and meta-analysis of 19 trials involving nearly 2,500 people found that a low-protein diet reduced the risk of kidney failure by about 40 percent and slowed the rate of eGFR decline, though it did not reduce overall mortality.22PubMed Central. Effect of diet protein restriction on progression of chronic kidney disease: A systematic review and meta-analysis The tricky part is calibrating protein restriction tightly enough to help the kidneys without causing malnutrition, especially in older or frail patients who need protein to maintain muscle.
When Acute Kidney Injury Becomes Chronic
CKD staging assumes a gradual, chronic process, but acute kidney injury (AKI), a sudden drop in kidney function from causes like severe infection, major surgery, or toxic medication exposure, can tip into chronic disease. AKI and CKD share common pathways involving cell death, persistent inflammation, and scar tissue formation, and a bout of AKI that appears to resolve can leave behind subclinical damage that accelerates future decline.23PubMed. Transition from acute kidney injury to chronic kidney disease: mechanisms, models, and biomarkers Anyone who has had a significant episode of AKI should have their kidney function monitored long afterward, because the risk of developing or worsening CKD remains elevated even once the initial crisis seems over.
Newer Biomarkers Beyond Creatinine
Research is pushing beyond creatinine and cystatin C toward biomarkers that can flag kidney damage earlier or predict who will progress fastest. KIM-1 (kidney injury molecule-1), a protein shed by injured kidney tubular cells, has emerged as a strong candidate. One study found KIM-1 to be the best marker for diagnosing incident CKD, with levels rising as the disease developed, while another marker called uromodulin (UMOD) decreased as kidney function declined.24PubMed. Urinary biomarkers in kidney disease Other biomarkers under investigation, including NGAL and beta-trace protein, have shown higher levels in CKD patients compared to healthy controls, but their clinical roles are still being defined.25PubMed Central. Comparison of BTP, NGAL, KIM-1, & ADMA biomarkers in CKD and non-CKD subjects None of these has replaced eGFR and albuminuria as the standard staging tools yet, but they may eventually help identify patients at high risk before eGFR begins its measurable decline.
The Gut-Kidney Axis
One of the more surprising lines of CKD research involves the gut. As kidney function falls, the intestine partially takes over the role of waste excretion, and the biochemical environment of the gut shifts. This change favors bacteria that produce uremic toxins while suppressing bacteria that produce beneficial short-chain fatty acids.26PubMed Central. Gut Microbiome in Patients with Chronic Kidney Disease Stages 4 and 5: A Systematic Literature Review The resulting microbial imbalance damages the gut lining, allowing bacterial fragments and toxins to cross into the bloodstream, which fuels the chronic inflammatory state characteristic of CKD.27PubMed. Link between gut microbiota dysbiosis and chronic kidney disease These gut-derived toxins, particularly indoxyl sulfate and p-cresyl sulfate, are the same compounds implicated in cardiovascular damage and CKD progression, creating a vicious cycle. This area of research is still young, but it suggests that managing the gut microbiome, whether through diet, probiotics, or other interventions, could become part of CKD treatment in the future.
Cognitive Effects of Advancing CKD
The brain may not be an obvious target of kidney disease, but the two organs share a vulnerability. The tiny blood vessels of the kidney and brain are structurally similar, and risk factors like high blood pressure and diabetes damage both. Beyond those shared risks, the uremic toxins that accumulate as kidney function drops can alter the cells lining the blood-brain barrier, making it more permeable and allowing neurotoxic compounds to reach brain tissue.28JAMA Network Open. Chronic Kidney Disease Severity and Risk of Cognitive Impairment Patients with advanced CKD report problems with memory, concentration, and processing speed at rates higher than age-matched peers, and research into the specific pathways connecting kidney failure and cognitive decline is ongoing.
Choosing Between Dialysis and Conservative Care at Stage 5
When kidney function drops into stage 5, the default expectation for most patients is starting dialysis or pursuing a transplant. A kidney transplant, when feasible, offers the best outcomes: lower mortality, fewer cardiovascular events, and substantially better quality of life compared to staying on dialysis, with those advantages growing over time.29PubMed. Systematic review: kidney transplantation compared with dialysis in clinically relevant outcomes In cost terms, the two are comparable over five years, but transplantation avoids years of dialysis sessions and produces more life-years of good quality.30Saudi Journal of Kidney Diseases and Transplantation. Cost-Effectiveness of Kidney Transplantation Compared with Chronic Dialysis In End-Stage Renal Disease
But transplant is not an option for everyone, particularly older patients with multiple serious illnesses. For these individuals, conservative kidney management, a palliative approach that focuses on symptom control and quality of life without dialysis, is increasingly recognized as a legitimate choice. A systematic review found that conservative management resulted in median survival of at least six months, ranging up to about two years, and that any survival advantage of dialysis over conservative care diminished substantially in patients with heavy comorbidity burdens, especially ischemic heart disease.31PubMed Central. Conservative management of end-stage renal disease without dialysis: a systematic review Quality of life in preliminary comparisons was similar between the two approaches, and patients managed conservatively often spend less time in hospitals.32PubMed Central. Recommendations for the Care of Patients Receiving Conservative Kidney Management: Focus on Management of CKD and Symptoms The conversation about whether to start dialysis or pursue conservative management is deeply personal, centering on what matters most to the patient: maximum time alive, or maximum comfort and independence with the time remaining.